Gilead Present Results of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV at CROI

March 10, 2021 Auto Bot Clinical Trials, Gilead, HIV, lenacapavir, results, Treatment, Trial 0

Shots:

  • The P-II/III CAPELLA trial involves assessing lenacapavir (SC, every 6mos.) vs PBO in 36 participants in a ratio (2:1) with multi-drug resistant HIV-1 infection
  • The study demonstrated virologic suppression @26wks., viral load reduction from baseline of ≥ 0.5 log10 copies/mL for 14days functional monothx. period (88% vs 17), low (150 mg/kg) and high dose (300 mg/kg) of GS-CA1 groups showed 86% and 96% infection risk reduction respectively and was well tolerated
  • Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV infection

Click here ­to­ read full press release/ article | Ref: Gilead | Image: PRNews

The post Gilead Present Results of Lenacapavir in P-II/III CAPELLA Trial for the Treatment of HIV at CROI first appeared on PharmaShots.